🏢 官网IRPLXQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 09-07(美东日)仅日期·⟳ 抓取 09-08 21:37:53回填·⚡ 决策 09-13 20:59:23·44.2 天前
Protalix BioTherapeutics（PLX.US）宣布CFO将出席9月H.C. Wainwright与摩根士丹利两场投资者会议，属常规活动通知
这是一份典型的IR日程类新闻稿：只披露CFO将出席两场投资者会议及直播链接，不含任何新增财务数据、指引、订单、合作条款、临床/监管进展或资本行动。事件本身对Protalix（PLX.US）的收入、利润、管线价值或证券供需没有可量化的增量影响，方向为中性，不存在正期望的交易结构。对合作方Pfizer（PFE.US）、会议主办方Morgan Stanley（MS.US）更无因果敞口。因此不进入行情、先例或供应链研究，直接AVOID。
📄 原文PLX↗ 原文
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
CARMIEL, Israel , Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutica…
不做 Protalix BioTherapeutics（PLX.US）
公告只是CFO出席2026-09-14 H.C. Wainwright大会与09-16摩根士丹利医疗大会的日程通知（附直播/回放链接），全文无财务数据、指引、订单、临床或监管进展、融资与人事变动；Elfabrio/Chiesi、Elelyso/Pfizer、PRX-115 Phase 2 RELEASE、PRX-119均为逐字重复的标准公司简介，不构成本次新增事实。materiality为零、方向中性，没有可校准的止盈止损与交易边界，因此不做。另：稿件日期2026-09-0…
不做 Pfizer（PFE.US）
仅在Protalix标准公司简介中作为Elelyso全球合作伙伴被提及，本次公告不涉及任何合作条款、里程碑、销售或供应变化，无因果敞口，且相对Pfizer体量materiality为零。
不做 Morgan Stanley（MS.US）
仅为会议主办方，一家小型生物医药公司出席其年度医疗大会对摩根士丹利业务与盈利无任何可辨识影响。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实层：全文核心只有两条日程（9/14 H.C. Wainwright 演讲、9/16 Morgan Stanley 炉边对话）加直播/回放链接与IR联系人，其余段落是逐字重复的公司标准简介（Elfabrio/Chiesi、Elelyso/Pfizer、PRX-115 Phase 2 RELEASE、PRX-119、ProCellEx）。影响链层：投资者会议出席属于关注度/流动性事件，不改变任何已知的管线状态、商业化里程碑或财务基线；即使管理层在会上做更新，那也将是届时新出现的独立催化，需以当时的新事实另行研判，而非现在预交易。价格/证据层：无金额、无预期差可算，materiality 为零，因此没有可校准的 tp/sl，也没有可定位的交易边界。结论：无事件、无增量事实、无可交易催化，对PLX.US及其提及的合作方一律不做。若后续会议期间出现指引上调、PRX-115 Phase 2 数据、Elfabrio销售/新市场批准或融资等实质披露，才构成新的研判对象。
主要风险
- 唯一需注意的是信息时效而非交易风险：会议实际在2026-09-14至09-16举行，会中管理层若披露PRX-115 Phase 2 RELEASE进展、Elfabrio商业化数据或融资计划，将形成新的、需独立研判的催化，本公告本身不能作为该催化的交易依据
- 本档案标注created_ms缺失、无可靠事件时点，正文自述日期为2026-09-08（相对now 2026-09-13已过5天），即便存在边际关注度效应也已被时间消化
先例如何影响了这次决策
对本次决策的影响:先例研究未执行，也未影响结论——早停理由是事件本身不含可交易增量事实，而非先例不足
方向:不适用：本事件无方向（NEUTRAL），先例统计不能为无增量的会议通知创造期望值
涨幅量级:不适用：无金额、无预期差，没有可校准的幅度锚
形态:不适用：未检索先例，因不存在需要判断见光死/高开低走的交易结构
原文全文
展开原文 · 2,838 字
CARMIEL,
Israel
,
Sept. 8, 2026
/PRNewswire/ --
Protalix BioTherapeutics, Inc.
(NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that
Gilad Mamlok
, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in
New York City
,
New York
:
H.C. Wainwright
28th Annual
Global Investment Conference
Date:
September 14-16, 2026
Company Presentation Date & Time:
Monday, September 14, 2026
, 2:00 p.m. EDT
Morgan Stanley 24th Annual Global Healthcare Conference
Date:
September 14-16, 2026
Fireside Chat Date & Time:
Wednesday, September 16, 2026
, 1:05 p.m. EDT
A live audio webcast of the Morgan Stanley fireside chat will be available at
https://cc.webcasts.com/morg007/091426a_js/?entity=125_OG1TMTP
, and on the Events Calendar of the Investors section of the Company's website,
www.protalix.com
. An archived replay will be available following the event.
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are available in multiple markets. These recombinant therapeutic proteins are expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. Protalix's global partner for Elfabrio® (pegunigalsidase alfa-iwxj), approved for Fabry disease in the United States, the European Union, and additional markets, is Chiesi Global Rare Diseases. Elelyso® (taliglucerase alfa) for Gaucher disease is approved in 23 markets and partnered with Pfizer Inc. worldwide, with the exception of Brazil, where Protalix partners with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health. Protalix's development portfolio includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, currently in the Phase 2 RELEASE trial; PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases; and research programs in rare renal diseases. To learn more, please visit
www.protalix.com
.
For Investor Inquiries:
Mike Moyer, Managing Director
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-upcoming-september-2026-investor-conferences-302872165.html
SOURCE Protalix BioTherapeutics, Inc.
Israel
,
Sept. 8, 2026
/PRNewswire/ --
Protalix BioTherapeutics, Inc.
(NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that
Gilad Mamlok
, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in
New York City
,
New York
:
H.C. Wainwright
28th Annual
Global Investment Conference
Date:
September 14-16, 2026
Company Presentation Date & Time:
Monday, September 14, 2026
, 2:00 p.m. EDT
Morgan Stanley 24th Annual Global Healthcare Conference
Date:
September 14-16, 2026
Fireside Chat Date & Time:
Wednesday, September 16, 2026
, 1:05 p.m. EDT
A live audio webcast of the Morgan Stanley fireside chat will be available at
https://cc.webcasts.com/morg007/091426a_js/?entity=125_OG1TMTP
, and on the Events Calendar of the Investors section of the Company's website,
www.protalix.com
. An archived replay will be available following the event.
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are available in multiple markets. These recombinant therapeutic proteins are expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. Protalix's global partner for Elfabrio® (pegunigalsidase alfa-iwxj), approved for Fabry disease in the United States, the European Union, and additional markets, is Chiesi Global Rare Diseases. Elelyso® (taliglucerase alfa) for Gaucher disease is approved in 23 markets and partnered with Pfizer Inc. worldwide, with the exception of Brazil, where Protalix partners with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health. Protalix's development portfolio includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, currently in the Phase 2 RELEASE trial; PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases; and research programs in rare renal diseases. To learn more, please visit
www.protalix.com
.
For Investor Inquiries:
Mike Moyer, Managing Director
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-upcoming-september-2026-investor-conferences-302872165.html
SOURCE Protalix BioTherapeutics, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。